Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Juvaris BioTherapeutics has initiated a Phase I clinical trial of its lead compound, JVRS-100. The trial will compare the safety, tolerability and immunogenicity of the JVRS-100 adjuvant co-administered with a commercial influenza vaccine compared to vaccine alone.
Subscribe to our email newsletter
The randomized, double blind, controlled Phase I trial is expected to enroll 128 healthy subjects in four treatment cohorts. The study will evaluate a licensed trivalent, inactivated, split influenza vaccine with ascending dose levels of JVRS-100 compared to the vaccine alone. JVRS-100 will also be studied with reduced doses of the influenza vaccine to assess its effectiveness and vaccine dose-sparing effects.
Primary objectives of the study are to assess the safety and tolerability of the JVRS-100 adjuvant and its ability to enhance immune responses (both antibody and cellular immunity) to the influenza vaccine.
Grant Pickering, president and CEO of Juvaris, said: “This double blind trial will evaluate varying dose amounts of JVRS-100 and is designed to provide safety information, dose determination and the primary immunological response data used to determine efficacy for adjuvanted vaccines.”